Stevanato (STVN)

• Market cap: $5.95B
• 1 day: -0.67%
• 5 days: -5.31%
• 1 month: 2.15%
• 3 months: -4.88%
• 6 months: 10.49%
• Year to date: -6.79%
• 1 year: -25.61%
• 5 years: 6.05%
• 10 years: 6.05%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Employees: 5,521

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

15% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 20

9% more capital invested

Capital invested by funds: $1.08B [Q3] → $1.19B (+$103M) [Q4]

7% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 44

0.5% more ownership

Funds ownership: 109.54% [Q3] → 110.05% (+0.5%) [Q4]

0% more funds holding

Funds holding: 129 [Q3] → 129 (+0) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

71% less call options, than puts

Call options by funds: $15K | Put options by funds: $52K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $24 13% upside
• Avg. target: $24 13% upside
• High target: $24 13% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

UBS John Sourbeer 0% 1-year accuracy 0 / 3 met price target

13% upside $24

Neutral Maintained

7 Mar 2025